Biosilu Healthcare AG (1YA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Biosilu Healthcare AG (1YA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011872
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Biosilu Healthcare AG (Biosilu Healthcare), formerly Amp Biosimilars AG is a life science company that develops and commercializes biopharmaceuticals. The company’s product pipeline comprises biosimilar development projects on immune disorders and cancer. It offers products in therapeutic areas of infectious diseases, fertility, tumor indications and other rare diseases. Biosilu Healthcare also provides advises for Asian biopharmaceutical companies and investors in outreach to Western markets, partners and investment opportunities. The company develops products with a clinical-proof-of-concept in areas of high medical needs in Asia. It partners with western biopharmaceutical companies. The company operates in Germany and China. Biosilu Healthcare is headquartered in Frankfurt, Germany.

Biosilu Healthcare AG (1YA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Biosilu Healthcare AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Biosilu Healthcare AG, Medical Devices Deals, 2011 to YTD 2017 9
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
amp biosimilars Enters into Licensing Agreement for ABY-021 Biosimilar 11
amp biosimilars Enters into Licensing Agreement for Biosimilar 12
Equity Offering 13
Biosilu Healthcare Raises USD0.5 Million in Private Placement of Shares 13
amp biosimilars Raises USD28.67 Million in IPO 14
Biosilu Healthcare AG – Key Competitors 15
Biosilu Healthcare AG – Key Employees 16
Biosilu Healthcare AG – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Jun 28, 2016: amp biosimilars announces Klaus K. Wilgenbus as new CEO 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Key Facts 2
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Biosilu Healthcare AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Biosilu Healthcare AG, Deals By Therapy Area, 2011 to YTD 2017 8
Biosilu Healthcare AG, Medical Devices Deals, 2011 to YTD 2017 9
Biosilu Healthcare AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
amp biosimilars Enters into Licensing Agreement for ABY-021 Biosimilar 11
amp biosimilars Enters into Licensing Agreement for Biosimilar 12
Biosilu Healthcare Raises USD0.5 Million in Private Placement of Shares 13
amp biosimilars Raises USD28.67 Million in IPO 14
Biosilu Healthcare AG, Key Competitors 15
Biosilu Healthcare AG, Key Employees 16

★海外企業調査レポート[Biosilu Healthcare AG (1YA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Electricity Generating Public Co Ltd (EGCO):企業の財務・戦略的SWOT分析
    Electricity Generating Public Co Ltd (EGCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • XState Resources Ltd (XST):企業の財務・戦略的SWOT分析
    Summary XState Resources Ltd (XST) is an oil and gas exploration and development company. The company’s business activities include acquisition, exploration, production and development of oil and gas assets. It holds interest in producing gas wells and associated land leases and production and pipel …
  • Nuclear Power Corporation of India Ltd-エネルギー分野:企業M&A・提携分析
    Summary Nuclear Power Corporation of India Ltd (NPCIL) designs, constructs, commissions and operates nuclear power reactors. It is controlled and governed by the Department of Atomic Energy (DAE), Government of India. The company generates power from nuclear with pressurized heavy water reactor, lig …
  • KYORIN Holdings Inc (4569):製薬・医療:M&Aディール及び事業提携情報
    Summary KYORIN Holdings Inc (KYORIN), formerly known as KYORIN Co.,Ltd., is a holding company. Its business activities include controlling, administering and supporting companies, which conduct various businesses by holding the shares of those companies. The company through its subsidiaries carries …
  • Fluidigm Corp (FLDM)-医療機器分野:企業M&A・提携分析
    Summary Fluidigm Corp (Fluidigm) formerly known as Mycometrix Corporation, is a biotechnology company which manufactures life-science tools and creates technologies based on microfluidics and mass cytometry. The company’s products systems include biomark HD system, access array system, C1 system, ca …
  • Lund University-製薬・医療分野:企業M&A・提携分析
    Summary Lund University (LNU) is an educational service provider that offers master and bachelor programmes. It offers education and research in the areas of engineering, economics and management, science, law, social sciences, medicine, humanities, theology, fine art, music and others. The universi …
  • Molson Coors Brewing Co (TAP):企業の財務・戦略的SWOT分析
    Molson Coors Brewing Co (TAP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Acasti Pharma Inc (ACST):製薬・医療:M&Aディール及び事業提携情報
    Summary Acasti Pharma Inc (Acasti), a subsidiary of Neptune Technologies & Bioressources Inc, is a biopharmaceutical company that conducts research, development, and commercialization of krill oil-based forms of omega-3 fatty acids. The company develops phospholipid therapies for abnormalities in bl …
  • National Bank Of Kuwait Sak
    National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report Summary National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Assembly Biosciences Inc (ASMB)-製薬・医療分野:企業M&A・提携分析
    Summary Assembly Biosciences Inc (Assembly), formerly Ventrus Biosciences Inc is a biotechnology company that discover, develops and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as chronic hepatitis B virus (HBV) and microbioti …
  • American Tower Corporation:企業の戦略・SWOT・財務情報
    American Tower Corporation - Strategy, SWOT and Corporate Finance Report Summary American Tower Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Development Center for Biotechnology-製薬・医療分野:企業M&A・提携分析
    Summary Development Center for Biotechnology (DCB) is a non-profit organization that provides support to biotechnology and pharmaceutical companies. The organization develops biotech industry through its cooperation and industrialization, key technologies, infrastructure building, research and devel …
  • Nanomerics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Nanomerics Ltd (Nanomerics) is a healthcare solution provider that develops drug delivery solutions for poorly water soluble drugs, nucleic acids and peptides. The company offers products such as METDoloron, METSporine, METAmphizon, METEnkalon, MET undisclosed, MET ocular undiscl, ocular und …
  • Raytheon Co:企業の戦略・SWOT・財務情報
    Raytheon Co - Strategy, SWOT and Corporate Finance Report Summary Raytheon Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Atreca Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Atreca Inc (Atreca) is a biotechnology company that develops and develops novel therapies based on the human immune response. The company develops proprietary immune repertoire capture technology that act as an engine for the discovery and development of antibody based therapeutics, diagnost …
  • Urban Outfitters Inc:戦略・SWOT・企業財務分析
    Urban Outfitters Inc - Strategy, SWOT and Corporate Finance Report Summary Urban Outfitters Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Rex Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    Rex Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary Rex Energy Corp (Rex Energy) is an independent energy company. It carries out the acquisition, production, exploration and development of condensate, natural gas and natural gas liquids. It holds pro …
  • Terme Dobrna D.D.:企業の戦略・SWOT・財務分析
    Terme Dobrna D.D. - Strategy, SWOT and Corporate Finance Report Summary Terme Dobrna D.D. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Drugs for Neglected Diseases initiative:製薬・医療:M&Aディール及び事業提携情報
    Summary Drugs for Neglected Diseases initiative (DNDi) is a non-profit drug research and development (R&D) organization which discovers and develops new drugs for neglected diseases. The organization develops therapeutics for the treatment of various diseases such as human African trypanosomiasis (H …
  • HTL International Holdings Limited:企業の戦略的SWOT分析
    HTL International Holdings Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆